Michael Seckler
Chief Executive Officer chez EVOME MEDICAL TECHNOLOGIES INC.
Fortune : - $ au 31/03/2024
Profil
Michael D.
Seckler is currently the Chief Executive Officer & Director at Evome Medical Technologies, Inc. He is also a Director at GLyPharma Therapeutic, Inc. Previously, he held the position of Vice President-Global Marketing at Ferring Pharmaceuticals, Inc. from 2017 to 2019.
From 2020 to 2023, he served as the Chief Operating Officer at FerGene, Inc. Mr. Seckler completed his undergraduate degree and MBA at The Pennsylvania State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 24/07/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Michael Seckler
| Sociétés | Poste | Début |
|---|---|---|
| EVOME MEDICAL TECHNOLOGIES INC. | Chief Executive Officer | 13/06/2023 |
GLyPharma Therapeutic, Inc.
 GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Director/Board Member | - |
Anciens postes connus de Michael Seckler
| Sociétés | Poste | Fin |
|---|---|---|
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Chief Operating Officer | 01/05/2023 |
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Sales & Marketing | 01/12/2019 |
Formation de Michael Seckler
| The Pennsylvania State University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EVOME MEDICAL TECHNOLOGIES INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Health Technology |
GLyPharma Therapeutic, Inc.
GLyPharma Therapeutic, Inc. BiotechnologyHealth Technology GLyPharma Therapeutic, Inc. develops oncology therapeutic treatment. It engages in the development of the clinical efficacy of FE 203799, a novel proprietary Glucagon-Like Peptide-2(GLP-2) analogue exerting unique pharmacological effects in a first-in-class, meaningful indication for patients with hematological malignancies receiving myelotoxic therapies. The company was founded in August 2012 and is headquartered in Montreal, Canada. | Health Technology |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Health Technology |
